Goalkeeper Willy Caballero welled up on the Wembley turf after winning the Capital One Cup for Manchester City.The Argentinian’s place in City’s starting line-up came under scrutiny after some unconvincing performances in the competition, with regular stopper Joe Hart waiting in the wings.But boss Manuel Pellegrini stuck by Caballero for the final and was repaid as the 34-year-old saved three shoot-out penalties for a 3-1 win after the tie had ended 1-1 after extra-time.“It’s a shame we conceded a goal because we defended really well today,” said Caballero.“It was really important that we won this trophy, for the team and for myself.“I watched all the penalties last night but I talked with my goalkeeper coach and with Joe [Hart] now but I like to make my decision when I’m in goal.“It was a really hard week for me with the decision [to not play Hart] for the coach but now I don’t have to say anything, I just have to enjoy and feel great in this moment.”Victorious City manager Pellegrini added: I think we deserved to win the game, we missed too many chances, played better than Liverpool.”On sticking with Caballero, he added: “I prefer to win it this way, because I was pleased to win the title for the players, fans, the staff but for Willy.“I preferred to lose the title than lose the word (of picking him). We are working hard, in the middle of the season, it is important for us to keep fighting now.“I was concerned about the amount of chances we missed. After that we played better in extra-time.“It’s a very important moment, and it’s always very special to win a title at Wembley.”
After more than nine years of leadership, Pandora CEO, President and Chairman Joe Kennedy has resigned, making the announcement during Pandora’s quarterly earnings call on Thursday. The company’s board of directors has formed a search committee to find a suitable successor, and Kennedy will stay in his current role until the replacement is brought in.Kennedy and Pandora wished to wind down their relationship on a positive note, citing milestones like 67 million monthly active listeners and 70% market share. But most telling were the company’s revenue and income figures. In fiscal 2013, Pandora totaled $427.1 million in revenue and $255.9 million in mobile revenue, with $125.1 million in revenue for the quarter that ended on January 31.While those numbers beat Wall Street expectations and represent record revenue for the company, it still wasn’t enough to push Pandora into profitability – and Wall Street doesn’t like it when a post-IPO company is growing but still loses money. That likely translated into Kennedy’s decision to step down.On that $125 million in Q4 revenue, Pandora took a quarterly loss of $14.6 million (9 cents per share), which exceeds its year-ago quarterly loss of $8.5 million (5 cents per share) on revenue of $81 million. Given the long string of losses, Pandora has been aggressively seeking ways to wring more cash from its subscribers, including limits on free listening and a fierce lobbying effort against royalty fees.(See also Pandora Remixes Its Free Listening Limits.) The Oakland, Calif.-based music recommendation service has had an up-and-down ride on the market since its IPO in the summer of 2011. Initially, Pandora opened at $16 per share and jumped into the $20s, but has since hovered just into the double-digit mark as the company scrambles to find ways to turn a profit.(See also Could Music Licensing Costs Kill Pandora? Ask Lastfm.)Despite the tumultuous relationship with investors, Wall Street seems to be responding well to Kennedy’s decision: Pandora shares jumped almost 20%, to $13.96, in after-hours trading. 4 Keys to a Kid-Safe App 5 Outdoor Activities for Beating Office Burnout Tags:#internet radio#Pandora#streaming music Related Posts nick statt 9 Books That Make Perfect Gifts for Industry Ex… 12 Unique Gifts for the Hard-to-Shop-for People…
The Supreme Court on Wednesday seemed to agree with the Centre’s proposal to let 40 lakh people, excluded from the final draft of the National Register of Citizens (NRC) in Assam, to produce additional documents to prove their legacy.Justice Ranjan Gogoi orally observed that the court agreed with the suggestion made by Assam NRC Co-ordinator Prateek Hajela in his report that those left out of the draft NRC could submit any one of the 10, of a total 15 documents in List-A of the Centre’s draft Standard Operating Procedure (SOP) for claims and objections.He said claimants could submit any of the 10 documents, provided they were authenticated by the relevant authority which issued them. “We are allowing only 10 because the other five can be cooked up,” Justice Gogoi told Attorney-General K.K. Venugopal. The Bench gave the government two weeks to respond to Mr. Hajela’s suggestion. The court deferred the process of receipt of claims and objections, and posted the next hearing for September 19.The court further refused to provide a copy of the full report of Mr. Hajela to the Centre.“We are extremely interested in having a copy,” Mr. Venugopal submitted.To this, Justice Gogoi replied that “you may be interested, but we have to balance it. The court has called for the report, now it is the discretion of the court to give it to you or not. First you respond to this suggestion (of Mr. Hajela), then we will see about it”.Later, in the court’s order, Justice Gogoi recorded that “the Attorney General has sought a copy of the co-ordinator’s report. We are of the view that what has been set out in the order (of the court) would be sufficient for the Union of India, stakeholders to indicate their views on it”.
January 25, 2018 KUSI Newsroom, MTS to increase frequency of some of its busiest bus routes around San Diego SAN DIEGO (KUSI) — Metropolitan Transit System officials Thursday announced it will increase the frequency of some of its busiest bus routes beginning next week.Under MTS’s Transit Optimization Plan, more than 30 routes will have a frequency of 15 minutes or quicker by the time the plan is fully implemented in June at a cost of $2 million, according to the agency.On Jan. 28, MTS will roll out the first changes on some its most frequently traveled routes. Among them is Route 3, which services Hillcrest, Balboa Park and the Gaslamp Quarter, which will see weekday frequency increase from 15 to 12 minutes and Sunday frequency increased from 60 minutes to 30 minutes.Route 5, which services downtown, Stockton, Chollas View and Euclid, will see its weekday frequency increased from 15 to 12 minutes.Route 950, which links Otay Mesa and Iris Avenue Station, will now run every 10 minutes during morning peak hours.Other routes are being split in two to increase reliability.“We know that frequency and speed of service are the keys for our current riders and attracting new riders,” MTS Chief Executive Paul Jablonski said. “We are investing into our system to make it as convenient and efficient as possible. Hundreds of thousands of people already choose transit every day. We’re working hard to make our system an even more attractive choice for people all over the San Diego region.”A complete list of changes can be viewed at www.sdmts.com/TOP. Posted: January 25, 2018 KUSI Newsroom Categories: Local San Diego News FacebookTwitter
Biocon claims to take Syngene unit public by selling stake16K views00:00 / 00:00- 00:00:0000:00Biocon claims to take Syngene unit public by selling stake16K viewsBusinessBengaluru, Jan 23 (ANI): Biocon Ltd would list its research services business arm Syngene by selling up to 15 percent stake in a public offer, the company said, after reporting third-quarter earnings on Friday (January 23). Biocon had previously said it planned to list Syngene but had not given a timeline. Late on Thursday (January 22), it said its board had approved starting the process of listing and hiring merchant bankers to sell 10-15 percent from Biocon’s majority stake in the unit in the public offer. Separately, Biocon agreed with Gilead Sciences Inc to licence its chronic hepatitis-C product range, it said in a statement.Ventuno Web Player 4.50Bengaluru, Jan 23 (ANI): Biocon Ltd would list its research services business arm Syngene by selling up to 15 percent stake in a public offer, the company said, after reporting third-quarter earnings on Friday (January 23). Biocon had previously said it planned to list Syngene but had not given a timeline. Late on Thursday (January 22), it said its board had approved starting the process of listing and hiring merchant bankers to sell 10-15 percent from Biocon’s majority stake in the unit in the public offer. Separately, Biocon agreed with Gilead Sciences Inc to licence its chronic hepatitis-C product range, it said in a statement.